NCT05995691View on ClinicalTrials.gov

Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

November 24, 2014

Primary Completion Date

December 4, 2015

Study Completion Date

December 4, 2015

Conditions
Healthy Volunteers
Interventions
DRUG

ABP 501

SC injection

DRUG

Adalimumab

SC injection

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT05995691 - Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants | Biotech Hunter | Biotech Hunter